Drug intelligence / Profile preview

ALF301

Development stage: Preclinical
Lead developer: Allife Medicine
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Injection

Overview

ALF301 is an induced pluripotent stem cell (iPSC)-derived islet cell therapy being developed by Allife Medical Science and Technology for the treatment of Type 1 and Type 2 diabetes. The therapy is designed to replace or supplement dysfunctional pancreatic beta cells by providing functional, insulin-producing islet cells. By restoring the body's endogenous ability to produce insulin in response to blood glucose levels, ALF301 aims to improve glycemic control and potentially reduce or eliminate the need for exogenous insulin therapy. It is currently in the preclinical stage of development.

Beyond the preview

Go deeper on ALF301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALF301.

Explore the full profile